Summary of Insmed Phase IIIb ENCORE Study Conference Call Company and Industry - **Company**: Insmed - **Industry**: Pharmaceutical, specifically focusing on treatments for MAC (Mycobacterium avium complex) lung infections Core Points and Arguments 1. **Study Success**: The ENCORE trial demonstrated a statistically significant improvement in respiratory symptom scores for patients treated with ARIKAYCE compared to the placebo group, indicating its effectiveness in treating MAC lung infections [4][10] 2. **Culture Conversion**: The study showed that 82.4% of patients in the ARIKAYCE arm achieved culture conversion by month 13, compared to 55.6% in the control arm, with a highly significant difference of approximately 27 percentage points [14][15] 3. **Durability of Treatment**: The results indicated that the benefits of ARIKAYCE persisted even after treatment cessation, with 76.2% of patients maintaining culture conversion at month 15 [16][17] 4. **Regulatory Submissions**: Insmed plans to pursue regulatory submissions with the FDA and PMDA in the second half of the year, aiming to expand the label to include all patients with MAC lung infections, increasing the addressable patient population from around 30,000 to over 200,000 [6][22] 5. **Safety Profile**: The safety profile of ARIKAYCE was consistent with previous studies, with no new safety signals observed. The treatment discontinuation rate was 18.3%, lower than previous studies, indicating improved tolerability [20][21] 6. **Patient-Reported Outcomes**: The study utilized a validated patient-reported outcome tool, which is a first in this disease state, enhancing the credibility of the findings [5][9] 7. **Market Potential**: The expansion of the patient population and the positive results from the study are expected to lead to significant revenue growth, with potential market penetration anticipated in the next 12-24 months [57][76] Other Important Content 1. **Comparison to Standard of Care**: The study aimed to establish a new standard of care by demonstrating that ARIKAYCE, when added to a two-drug regimen, provides significant benefits in both symptoms and culture conversion [25][26] 2. **Long-term Benefits**: While the study did not specifically assess survival benefits, the durable culture conversion suggests potential long-term advantages for patients, including reduced risk of becoming refractory to treatment [29][31] 3. **Dysphonia Rates**: Dysphonia was reported in 50.7% of patients in the ARIKAYCE arm, but measures to mitigate this side effect have been identified, enhancing the overall benefit-risk profile [36][37] 4. **Real-World Applicability**: The trial population is considered representative of real-world treatment practices, which may facilitate the adoption of ARIKAYCE in clinical settings [42][43] 5. **International Market**: Japan is highlighted as a significant market opportunity due to a higher prevalence of MAC infections, with expectations for continued revenue generation from this region [72][73] This summary encapsulates the key findings and implications from the conference call regarding the ENCORE study and the future of ARIKAYCE in treating MAC lung infections.

FY 2025 Debt Investor Presentation Business & Strategic Overview 1 2 Unrivalled position as Ireland's national champion bank Embedded in every community across Ireland Powering 40% of all payments in the Irish economy 81% of our Irish PCA customers are digitally active c.200 locations > 4m customers across the Group #1 Mortgages c.33% PCA market share2 #2 Everyday Banking 42% Mortgage market share1 #1 Wealth for HNW €60bn AUM £6bn NI deposits £1bn NI loans #1 Irish Commercial bank >50% SME lending share ROI ...

NASDAQ: WRD To Transform Urban Living with Autonomous Driving Fourth Quarter and Full Year 2025 Financial Results HKEX: 0800 Disclaimer During today's event, we will make statements that may constitute "forward-looking" statements pursuant to the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "aims," "future," "intends," "plans," "believes," "estimates," "likely ...

GRAB ACQUISITION OF FOODPANDA TAIWAN GRAB ACQUISITION OF FOODPANDA TAIWAN Disclaimer Non-IFRS Financial Measures This document includes references to Adjusted EBITDA, which is a non-IFRS financial measure. Grab uses Adjusted EBITDA for financial and operational decision-making and as a means to evaluate period-to-period comparisons, and Grab's management believes that this non-IFRS financial measure provides meaningful supplemental information regarding its performance by excluding certain items that may no ...

Disclaimer Confidentiality This presentation is confidential and may not be reproduced or distributed to others at any time without our prior written consent. Forward-Looking Statements Camtek Investor Presentation February 2026 This presentation contains forward-looking statements within the meaning of the federal securities laws. You can identify these statements by our use of the words "anticipates," "assumes," "believes," "estimates," "expects," "guidance," "intends," "plans," "projects," "can," "could, ...

Divesting Taiwan operations March 23, 2026 Taiwan divestment marks a decisive first step to unlock shareholder value Executive summary 1. On a debt free cash free basis 2 ▪ As stated in our shareholder letter dated December 9, 2025, Delivery Hero remains fully committed to reviewing and executing strategic measures, aiming to create value for our shareholders ▪ The divestment of our Taiwan food delivery operations to Grab for USD 600m1 in cash marks an important first milestone transaction in our ongoing st ...

INVESTOR PRESENTATION March 2026 Safe Harbor Statement This presentation contains statements that reflect our views about our future performance and constitute "forward-looking statements" under the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "outlook," "believe," "anticipate," "appear," "may," "will," "should," "intend," "plan," "estimate," "expect," "assume," "seek," "forecast," and similar references to future periods. Our views about fu ...

This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 regarding future events or our future financial performance that involve certain contingencies and uncertainties. The forward-looking statements include, without limitation, statements with respect to the Company's anticipated financial results and statements regarding the Company's plans and expectations regarding the continuing development, commerci ...

Corporate Presentation MARCH 2026 © 2026 Cabaletta Bio. All rights reserved. Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document distributed at or in connection with the presentation (collectively, the "Presentation") has been prepared by Cabaletta Bio, Inc. ("we," "us," "our," "Cabaletta" or the "Company") and may co ...

Veolia Environnement Update Summary Company Overview - **Company**: Veolia Environnement (OTCPK: VEOE.F) - **Date of Briefing**: March 23, 2026 Key Industry Insights - **Geopolitical Context**: The company operates in a world marked by geopolitical tensions, particularly in the Middle East, which affects global trade and emphasizes the importance of environmental security as a matter of national security and economic sovereignty [2][8]. - **ESG Relevance**: The current instability reinforces the relevance of Environmental, Social, and Governance (ESG) strategies, as environmental challenges are now seen as security imperatives [2]. Financial Performance - **Revenue**: Achieved over EUR 44 billion in revenue, with EBITDA up 6.3%, exceeding guidance [3]. - **Profitability**: Current net income increased by 11.8% on average per year over the past two years, with profitability up 150 basis points [3]. - **Gross Profit Target**: Achieved a gross profit target of 9.4% two years ahead of schedule [4]. - **Leverage Ratio**: Maintained a leverage ratio of 2.79 times, below the 3 times threshold, indicating financial strength [4]. - **International Operations**: EBITDA increased by 9.3% outside Europe, driven by hazardous waste and water technologies [4]. Environmental Performance - **GreenUp Plan**: Two out of three GreenUp objectives achieved two years early, including saving nearly 1.6 billion cubic meters of fresh water and treating 9.2 million tons of hazardous waste [5][24]. - **Decarbonization**: Scope 1 and 2 emissions reduced by 18.6% compared to 2021, with a target to reduce coal-based activity to below 1% by 2030 [10][12]. - **Biodiversity Initiatives**: Aiming to deploy biodiversity action plans on 85% of sensitive sites by 2027, having already reached 80% [26]. Operational Highlights - **Employee Engagement**: Achieved an 85% employee engagement rate, significantly above the utilities benchmark, with a focus on safety and security [31]. - **Safety Improvements**: Workplace accidents down 75% over 15 years, with a 5% reduction this year [32]. - **Employee Shareholding**: Aiming for 10% employee shareholding to enhance trust and ownership among employees [33]. Strategic Initiatives - **Decarbonization Strategy**: Integrated into the business model, focusing on methane capture, energy efficiency, and coal exit plans [10][12]. - **Water Resource Management**: Advanced tools deployed to monitor water distribution, aiming to save 1.5 billion cubic meters of freshwater by 2027 [24]. - **Hazardous Waste Management**: Achieved treatment of 9.2 million tons of hazardous waste, ahead of the 2027 target [25]. Market Opportunities - **AI and Digital Strategy**: AI is central to improving operational efficiency, with a significant increase in efficiency attributed to AI and digital initiatives [42]. - **Recycling and Circular Economy**: The EU's support for recycling aligns with Veolia's strategy to secure supply chains and reduce dependency on imports [51]. Regional Focus - **Middle East Operations**: Revenue from the Middle East is approximately EUR 1 billion, with a focus on essential services like desalination and hazardous waste management [50][46]. - **Coal Exit Plans**: Successful coal exit strategies in Central Eastern Europe are scalable to other regions, with a focus on multi-fuel approaches [54][56]. Conclusion - **Value Proposition**: Veolia's unique value proposition lies in delivering environmental security that creates lasting shareholder value, addressing critical challenges such as water scarcity and pollution [7][8]. - **Future Outlook**: The company is well-positioned to continue its growth trajectory, leveraging its integrated business model that aligns sustainability with profitability [37].